We rank companies based on fund manager, research analyst and news sentiment
ARVN stock icon

Arvinas
ARVN

$35.78
1.68%
 

About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Employees: 445

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 20 analysts
0
News positive %
of 6 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

224% more first-time investments, than exits

New positions opened: 81 | Existing positions closed: 25

180% more capital invested

Capital invested by funds: $949M [Q3] → $2.66B (+$1.71B) [Q4]

135% more call options, than puts

Call options by funds: $3.41M | Put options by funds: $1.45M

100% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 8 (+4) [Q4]

51% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 43

37% more funds holding

Funds holding: 150 [Q3] → 206 (+56) [Q4]

27.21% more ownership

Funds ownership: 90.31% [Q3] → 117.52% (+27.21%) [Q4]

Research analyst outlook

20 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$20
44%
downside
Avg. target
$57
60%
upside
High target
$90
152%
upside

20 analyst ratings

17 positive
85%
neutral
15%
negative
0%
HC Wainwright & Co.
Andrew Fein
143%upside
$87
Buy
Maintained
15 Apr 2024
HC Wainwright & Co.
Andrew Fein
143%upside
$87
Buy
Maintained
12 Apr 2024
Truist Securities
Joon Lee
82%upside
$65
Buy
Reiterated
25 Mar 2024
Barclays
Peter Lawson
68%upside
$60
Overweight
Maintained
29 Feb 2024
HC Wainwright & Co.
Andrew Fein
152%upside
$90
Buy
Reiterated
28 Feb 2024

Financial journalist opinion

Based on 6 articles about ARVN published over the past 30 days